Personalized mRNA melanoma vaccine shows clinical success, reviving optimism for the platform
Moderna and Merck reported positive results from a personalized mRNA vaccine designed to treat melanoma in a recent clinical study.
The outcome is being hailed as a boost for mRNA technology, which previously gained fame through COVID-19 vaccines but has struggled with political and public skepticism.
Physician Ryan Sullivan of Mass General Brigham suggested that demonstrating a vaccine can fight cancer may help soften the stigma around the word "vaccine" and the technology itself.
Experts caution that broader acceptance will still require additional data and regulatory review, but the trial's success has renewed confidence in the platform's potential across other disease areas.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: After a rough stretch, mRNA gets a boost — at least for now”
read at STAT ↗
comments(0)
5-min edit window · permanent after that